Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	9/12/2006 6:47:09 PM
	Read Replies (1) of 285

More than a couple hours notice in a PR -- they must have some good news to report re the Oral formulation... +++++++++++++ Cardiome To Hold Conference Call prnews NASDAQ: CRME TSX: COM VANCOUVER, Sept. 12 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a teleconference call and webcast will be held on Wednesday, September 13, 2006 at 8:00am EST (5:00am PST) to discuss results from the Phase 2a pilot study for RSD1235 (oral). A press release will be issued prior to the call. The conference call will be hosted by Bob Rieder, Chief Executive Officer, Doug Janzen, President and Chief Business Officer and Dr. Charles Fisher, Executive Vice President and Chief Medical Officer. To access the conference call, please dial 416-644-3416 or 800-814-4853. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at www.cardiome.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next